medRxiv preprint doi: https://doi.org/10.1101/2020.02.28.20028514; this version posted March 3, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

The level of plasma C-reactive protein is closely related to the liver injury in patients with COVID-19

Lu Li[1,2#], Shuang Li[3#], Manman Xu[1,2], Sujun Zheng[1,2], Zhongping Duan[1,2], Yu Chen[1,2*], Junfeng Li[4*]

1 Difficult & Complicated Liver Diseases and Artificial Liver Center, Beijing You'an Hospital, Capital Medical University, Beijing, China, 100069; &2 Beijing Municipal Key Laboratory of Liver Failure and Artificial Liver Treatment Research, Beijing, China, 100069; &3 Hemodialysis Room, Urinary Center, Beijing You'an Hospital, Capital Medical University, Beijing, China,100069; &4 Institute of Infectious Diseases, Department of Infectious Diseases, The First Hospital of Lanzhou University, Lanzhou, Gansu 730000,P.R. China

*Corresponding author:

Yu Chen

Difficult & complicated liver diseases and artificial liver center, Beijing You'an Hospital, Capital Medical University, Beijing, 100069, China.

E-mail: chybeyond@163.com

Junfeng Li

Institute of Infectious Diseases, Department of Infectious Diseases, The First Hospital of Lanzhou University, 1 Donggangxi Road, 730000, Lanzhou, China

Email：junfenglee@126.com

#Co-first authors：

Lu Li and Shuang Li contributed equally to this work.

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

medRxiv preprint doi: https://doi.org/10.1101/2020.02.28.20028514; this version posted March 3, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Abstract

Aim:

Coronavirus disease 2019 (COVID-19) has rapidly become the most severe public health issue all over the world. Despite acute respiratory failure, liver dysfunction has also been observed in clinical settings This study aimed to investigate the factors involved with hepatic injury in COVID-19 patients.

Methods:

A total of 26 hospitalized patients who were diagnosed with COVID-19 treated at Beijing You'an Hospital were retrospectively analyzed. According to the diagnostic criteria, they were divided into mild group (n=3), ordinary group (n=6), serious group (n=11) and critical group (n=6). Blood count, blood chemistry, coagulation test, liver and renal function, C-reactive protein, procalcitonin, lactic acid, cardiac markers and arterial partial pressure was compared between these groups. Independent risk factors of ALT increase was selected.

Results:

There were 8 patients with ALT elevation in the patients with COVID-19, accounting for 30.8% (8/26). There was no difference in sex ratio between normal and elevated ALT population, and there was an increasing trend in age. The CRP index was significantly higher in the population with elevated ALT, and the increase of CRP was independently related to ALT level, and the OR value was 1.023 (P = 0.024).

Conclusions:

medRxiv preprint doi: https://doi.org/10.1101/2020.02.28.20028514; this version posted March 3, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

COVID-19 related hepatic injury may be a result of cytokine storm syndrome, a positive correlative relationship between the increase of CRP and liver injury. Early detection and timely treatment of hepatic injury is necessary.

Key word: Coronavirus disease 2019 (COVID-19), liver injury, Cytokine storm syndrome

Funding: National Key R&D Program of China（No.2017YFA0103000）; National Science and Technology Key Project on “Major Infectious Diseases such as HIV/AIDS, Viral Hepatitis Preventon and Treatment”（NO. 2017ZX10203201-005）;Beijing Municipal Administration of Hospitals Clinical Medicine Development of Special Funding Support（NO.ZYLX201806）

medRxiv preprint doi: https://doi.org/10.1101/2020.02.28.20028514; this version posted March 3, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Introduction

Novel coronavirus pneumonia（NCP）is a newly emerging infectious disease caused by a novel coronavirus mutant with outstanding symptoms of acute atypical pneumonia and pulmonary damage. Since December 2019, this new disease has rapidly become the most severe public health issue in China, threatening the overall health and socioeconomic well-being of our society[1-4]. Studies have shown that COVID-19, which belongs to the beta-coronavirus family, has distinct genetic differences from SARSr-CoV and MERSr-Cov[5]. In February 2020, the WHO announced the virus a novel coronavirus mutant and officially named it as coronavirus disease 2019 (COVID-19). Up until February 26th 2020, there have been 78,211 COVID-19 cases resulting in 2,720 deaths. Despite atypical pneumonia being the primary symptom, liver dysfunction has also been observed in clinical settings, indicating a possibility for COVID-19 to cause hepatic injury. However, the reason and mechanism behind the hepatic injury is still unclear. For the time being, there has been a lack of research regarding this issue and it remains controversial. Therefore, a more thorough investigation of the relationship between COVID-19 and hepatic injury is critical in terms of solving practical clinical problems as well as improving clinical treatment and cure rate. We selected the representative COVID-19 patients and focused on the characteristics of their hepatic injury and the possible influences from COVID-19, aiming to provide new clues and data for clinical diagnosis and treatment.

medRxiv preprint doi: https://doi.org/10.1101/2020.02.28.20028514; this version posted March 3, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Methods

Patient selection

For this retrospective, single-center study, we recruited 26 patients with COVID-19 from Jan 28 to Feb 22, 2020, at the You'an Hospital of Capital Medical University, Beijing, China. Diagnosis of COVID-19 and clinical classification according to the new coronavirus pneumonia diagnosis and treatment plan (trial version 6) developed by the National Health Committee of the People's Republic of China (http://www.nhc.gov.cn/). The clinical classifications are as follows: (1) mild, only mild symptoms, no sign of pneumonia in imaging. (2) ordinary, with fever, respiratory tract symptoms, and imaging shows pneumonia. (3) moderate, meet any of the following: a) respiratory distress, respiratory rate ≥ 30 beats / min; b) in the resting state, means oxygen saturation ≤ 93%; c) arterial blood oxygen partial pressure/ oxygen concentration ≤ 300mmHg (1mmHg = 0.133kPa). Pulmonary imaging showed that the lesions progressed more than 50% within 24-48 hours, and the patients were managed according to moderate case. (4) severe, one of the following conditions: a) respiratory failure occurs and requires mechanical ventilation; b) Shock occurs; c) ICU admission is required for combined organ failure. The research ethics was approved by the ethics committee of Beijing You'an Hospital of Capital Medical University(2020-022).

Baseline data collection

medRxiv preprint doi: https://doi.org/10.1101/2020.02.28.20028514; this version posted March 3, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Collect the laboratory data of 26 patients at admission. Laboratory assessments consisted of complete blood count, blood chemistry, coagulation test, liver and renal function, C-reactive protein, procalcitonin, lactic acid, cardiac markers, arterial partial pressure of oxygen and CT scan.

Statistical analysis

Age and days were represented by median (range), categorical variables by number (%), and laboratory data by mean (interquartile range). Compared the differences between the two groups with t-test, chi-square test or Mann-Whitney U test. logistic regression was used to select independent risk factors that affect ALT increase. Analyses were performed using SPSS 22.0 statistical package (SPSS, Inc., Chicago, IL, USA). P-value < 0.05 was considered statistically significant.

Results

Clinical characteristics of patients with COVID-19

The characteristics of patients with COVID-19 in the present study were shown in **Table 1**. The average age of the patients with COVID-19 was 65.81 years old, the sex ratio was similar. The average ALT value was 37.31U/L, and the AST level slightly increased. The average value of total bilirubin and direct bilirubin were in the normal range. The average level of creatinine was normal. C-reactive protein increased significantly, the average value of lymphocyte was close to the normal low value. The average value of creatine kinase was normal. In terms of clinical classification, the

medRxiv preprint doi: https://doi.org/10.1101/2020.02.28.20028514; this version posted March 3, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

proportion of severe patients was 42.3%, followed by common and critical patients. At the same time, the patient had no history of liver disease.

Characteristics of liver injury in patients with COVID-19

The results were shown in **Table 2.** There were 8 patients with ALT elevation in the whole population, accounting for 30.8% (8/26). There was no difference in sex ratio between normal and elevated ALT population, and there was an increasing trend in age. The bilirubin level was normal between the two groups. However, the CRP index was significantly higher in the population with elevated ALT. At the same time, neutrophils also increased. There was no significant difference in clinical classification between the two groups, however, the results showed that the proportion of severe patients in the ALT increased group was higher, reaching 62.5%.

The factor related to ALT elevation in Multivariate analysis

The CRP and neutrophils with significant differences in the univariate analysis were analyzed in logistic regression. It was found that the increase of CRP was independently related to ALT level, and the OR value was 1.023 (P = 0.024).

Discussion

Our study reported on the factors involved with hepatic injury in COVID-19 patients. It was noticed for the first time that the injury was closely related to CRP, indicative of an inflammatory response. This discovery gave new evidence for the mechanism of COVID-19 patient's hepatic injury.

medRxiv preprint doi: https://doi.org/10.1101/2020.02.28.20028514; this version posted March 3, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

As the number of patients diagnosed with COVID-19 infection continues to rise, it is apparent that, similar to SARS (Severe Acute Respiratory Syndrome), COVID-19 mainly causes pulmonary symptoms, but may simultaneously lead to the injury of non-pulmonary organs including the liver, kidneys and cardiac muscle[6-9]. A recent study published in *The Lancet* revealed that 43 out of 99 COVID-19 cases from the Wuhan Jinyintan Hospital had shown transaminase elevation (ALT or AST elevation), with one patient suffering severe hepatic injury (ALT 7590 U/L, AST 1445 U/L)[6]. However，no further research or explanation had been provided. The latest research from the Liver Cancer Institute at Zhongshan Hospital of Fudan University has shown that bile duct cell has high specific expression of coronavirus receptor ACE-2 and low expression of hepatocytes, indicating the capability of COVID-19 to bind to ACE-2 positive bile duct cells directly, leading to the dysfunction of the bile duct, while biliary epithelial cell plays a key role in liver regeneration and immunoreaction[7]. Additionally, most scholars believe that cytokine storm syndrome (CCS) and drug-induced liver injury may be the main mechanism behind hepatic injury. *The Lancet* also recently published a case report authored by Dr. Fusheng Wang's team from the Fifth Medical Center of PLA General Hospital (302 Hospital). On January 27 2020, Dr. Wang's team performed a pathological autopsy on a deceased COVID-19 patient. According to their report, the patient's liver biopsy specimen revealed medium microvascular lipoid degeneration and active inflammation in the hepatic lobule portal area[8]. Due to the usage of interferon α-2b, lopinavir/ritonavir on

medRxiv preprint doi: https://doi.org/10.1101/2020.02.28.20028514; this version posted March 3, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

the patient as treatment, there is difficulty in distinguishing within the pathological report whether the hepatic injury was caused by COVID-19 or a result of drug-induced liver injury.

Our research involved 26 COVID-19 patients, out of which, 8 patients with no underlying chronic liver disease developed hepatic injury while admitted (over the clinical course). The other 18 patients had no signs of hepatic injury. Among the 8 patients presenting with hepatic injury, one patient had moderate symptoms while seven were under clinical care, an indication that hepatic injury likely occurs in patients under critical care. This indication is consistent with Academician Nanshan Zhong and his team's recent clinical research on acute respiratory syndrome caused by COVID-19, published in the form of preprint[9]. Their research, which involved the largest scale of data so far, discovered that the abnormal rate of ALT and AST among critical COVID-19 patients are evidently higher than those among the non-critical patients（ALT，39.4% vs 18.2%，P<0.001 ；AST，28.1% vs 19.8%，P=0.043）. However, there was little statistical significance after we compared the two groups of our patients (P=0.338), which may be a result of the small number of samples.

The hepatic injury of the patients was mainly reflected through mild and medium elevation of ALT and AST, while elevation in serum-bilirubin was a rare occurrence. In our research, the highest ALT (629U/L) and the highest AST(1912U/L) was from a patient under critical care and resulted in mortality. As the disease developed, ALT of

medRxiv preprint doi: https://doi.org/10.1101/2020.02.28.20028514; this version posted March 3, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

most patients began to drop during the second week, while serum-bilirubin levels mostly remained consistent. Hence, the hepatic injury complication of COVID-19 patients can be considered as a temporary acute hepatic injury with a relatively rapid change of serum enzyme, most less than 200U/L, and with gradual recovery after one week. The combination of the preceding pathological report showing a medium microvascular lipoid degeneration, active inflammation in the hepatic lobule portal area, abnormal liver function and pathology strongly support the argument that the hepatic injury related to COVID-19 is an acute non-specific inflammation change.

In addition, when comparing the two groups of patients by single parameter and multiple parameters, we found that COVID-19 related hepatic injury is closely related to cytokine storm syndrome. Cytokine storm syndrome (CSS) is an overactive inflammatory response of the human body caused by infectious or non-infectious disease, which involves a persistent activation and reproduction of several kinds of lymphocytes and macrophages that will secrete huge amount of cytokine[10]. CSS is highly correlated to the pathogenicity of infectious diseases and the fatality rate of virus infections such as SARS[11,12]. CSS not only leads to pulmonary injury, but also the injury of non-pulmonary organs including the liver, kidneys and cardiac muscle. Because inflammatory cytokine is not listed as a routine test for admission, CRP can be used as a critical indicator of CSS. C reactive protein (CRP) is an acute phase protein that rapidly increase in the presence of infection or tissue damage. CRP plays an important role in the body immune process by activating complement and

medRxiv preprint doi: https://doi.org/10.1101/2020.02.28.20028514; this version posted March 3, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

enhancing phagocytosis, thereby eliminating pathogenic microorganisms and/or tissue cells that are damaged or necrotic. Our research revealed a positive correlative relationship between the increase of CRP and the increase of ALT, which signifies that COVID-19 related hepatic injury may be a result of CSS.

Our study also observed the patients involved in our research had a decline in albumin levels, though there was no obvious decline rate difference between the hepatic injury group and the control group, indicating that the result was not related to hepatic injury. The observed decline of albumin was more likely due to the exuberant protein synthesis caused by COVID-19 patients' hyper metabolic state presenting with fever, malnutrition and low caloric intake, suggesting the likely importance of nutritional support therapy.

There were some limitations in the study, most of patients are still in hospital, whose condition maybe change in follow-up. And the study has not included the final survival outcome. However, we focused on the early identification of critical cases for risk stratification and management. We expect the results can help alleviate the shortage of medical resources and manage liver injury in patients with COVID-19 infection.

In conclusion, hepatic injury is a likely complication of COVID-19 infection, presenting with a mild or medium increase in transaminase and an abnormal level of

medRxiv preprint doi: https://doi.org/10.1101/2020.02.28.20028514; this version posted March 3, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

bilirubin. Therefore, early detection and timely treatment of hepatic injury is necessary.

Reference

1. Zhu Na, Zhang Dingyu,Wang Wenling et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019.[J] .N. Engl. J. Med., 2020, 382: 727-733. doi:10.1056/NEJMoa2001017

2. Wang Chen, Horby Peter W, Hayden Frederick G, et al. A novel coronavirus outbreak of global health concern.[J] .Lancet, 2020, 395:470-473. doi:10.1016/S0140-6736(20)30185-9

3. Horton Richard,Offline: 2019-nCoV outbreak-early lessons.[J] .Lancet, 2020, 395: 322. doi:10.1016/S0140-6736(20)30212-9

4. Luo Guangxiang George, Gao Shou-Jiang. Global health concerns stirred by emerging viral infections.[J] .J. Med. Virol., 2020, 92: 399-400. doi:10.1002/jmv.25683

5. Lu Roujian, Zhao Xiang, Li Juan et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding.[J] .Lancet, 2020, 395: 565-574. doi:10.1016/S0140-6736(20)30251-8

6. Chen Nanshan, Zhou Min, Dong Xuan, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study.[J] .Lancet, 2020, 395: 507-513. doi:10.1016/S0140-6736(20)30211-7

7. Chai Xiaoqiang, Hu Longfei, Zhang Yan, et al. Specific ACE2 Expression in Cholangiocytes May Cause Liver Damage After 2019-nCov Infection. bioRxiv, 2020. doi: https://doi.org/10.1101/2020.02.03.931766

8. Xu Zhe,Shi Lei,Wang Yijin et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome.[J] .Lancet Respir Med, 2020, undefined: undefined.

medRxiv preprint doi: https://doi.org/10.1101/2020.02.28.20028514; this version posted March 3, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

doi:10.1016/S2213-2600(20)30076-X

9. Guan Weijie, Ni Zhengyi, Hu Yu, et al. Clinical characteristics of 2019 novel coronavirus infection in China. medRxiv, 2020. doi:https://doi.org/10.1101/2020.02.06.20020974

10. Tisoncik Jennifer R, Korth Marcus J, Simmons Cameron P, et al. Into the eye of the cytokine storm.[J] .Microbiol. Mol. Biol. Rev., 2012, 76: 16-32. doi:10.1128/MMBR.05015-11

11. Chen Jun, Subbarao Kanta. The Immunobiology of SARS*.[J] .Annu. Rev. Immunol., 2007, 25: 443-72. doi:10.1146/annurev.immunol.25.022106.141706

12. Duan Zhong-ping,Chen Yu,Zhang Jing et al. [Clinical characteristics and mechanism of liver injury in patients with severe acute respiratory syndrome].[J] .Zhonghua Gan Zang Bing Za Zhi, 2003, 11: 493-6. doi:10.3760/j.issn:1007-3418.2003.08.014

medRxiv preprint doi: https://doi.org/10.1101/2020.02.28.20028514; this version posted March 3, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Table 1. Characteristics of the patients with COVID-19

Indicators	Value
Age(years)	65.81±17.88
Sex: Female, n(%)	13(50)
ALT(U/L)	37.31±34.42
AST(U/L)	47.85±32.36
Albumin(g/L)	34.72±7.04
Total bilirubin (μmol/L)	13.18±15.77
Direct bilirubin (μmol/L)	4.65±8.65
Creatinine (μmol/L)	67.83±22.93
Lactic acid(mmol/L)	1.68±0.82
C-reactive protein(mg/L)	53.42±52.11
White blood cell (10^9/L)	5.44±2.33
Red blood cell (10^12/L)	4.47±0.65
Hemoglobin (g/L)	135.12±21.21
Platelet (10^9/L)	190.73±80.88
Neutrophil count(×10^9/L)	4.04±2.26
Lymphocyte(×10^9/L)	0.91±0.35
Monocyte(×10^9/L)	0.35±0.17
Creatine Kinase(U/L)	197.42±338.73
Creatine Kinase Isoenzyme-MB(U/L)	2.62±3.56
TroponinI	0.05±0.09
Myoglobin	136.55±134.82
INR	1.10±0.10
History of liver diseases	None
Clinical types，n(%)	
Mild type	3(11.5)
Ordinary type	6(23.1)
Severe type	11(42.3)
Critical type	6(23.1)

medRxiv preprint doi: https://doi.org/10.1101/2020.02.28.20028514; this version posted March 3, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Table 2. Indicators of ALT normal and elevation group of patients with COVID-19

Indicators	ALT normal group (n=18)	ALT elevation group (n=8)	P value
Age(years)	64.17±19.50	69.50±13.99	0.494
Sex: Female，n(%)	9(50)	4(50)	1.000
Albumin(g/L)	36.21±6.70	31.38±7.04	0.108
Total bilirubin (μmol/L)	13.22±18.91	13.09±4.45	0.120
Direct bilirubin (μmol/L)	5.09±10.43	3.68±1.31	0.062
Creatinine (μmol/L)	72.94±25.42	57.63±12.83	0.125
Lactic acid(mmol/L)	1.49±0.87	2.01±0.65	0.152
C-reactive protein(mg/L)	36.58±52.06	91.30±27.31	0.006
White blood cell (10^9/L)	4.90±2.08	6.66±2.53	0.073
Red blood cell (10^12/L)	4.52±0.62	4.38±0.75	0.505
Hemoglobin (g/L)	136.53±16.81	132.13±29.70	0.930
Platelet (10^9/L)	177.39±63.79	220.75±109.50	0.291
Neutrophil count(×10^9/L)	3.40±1.84	5.46±2.57	0.029
Lymphocyte count	0.98±0.38	0.76±0.20	0.063
Monocyte count	0.39±0.18	0.26±0.11	0.087
Creatine Kinase(U/L)	91.06±77.80	410.13±535.23	0.118
Creatine Kinase Isoenzyme-MB(U/L)	2.89±4.09	2.10±2.32	0.903
TroponinI	0.06±0.11	0.03±0.03	0.490
Myoglobin	116.25±141.06	167.00±127.67	0.247
INR	1.07±0.10	1.15±0.07	0.067
Clinical classification, n(%)			
Mild type	3(16.7)	0(0)	0.388
Ordinary type	5(27.8)	1(12.5)	
Severe type	6(33.3)	5(62.5)	
Critical type	4(22.2)	2(25)	